These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29485874)

  • 21. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
    Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
    Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MutT Homolog 1 (MTH1): The Silencing of a Target.
    Papeo G
    J Med Chem; 2016 Mar; 59(6):2343-5. PubMed ID: 26924380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
    Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
    J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition.
    Bräutigam L; Pudelko L; Jemth AS; Gad H; Narwal M; Gustafsson R; Karsten S; Carreras Puigvert J; Homan E; Berndt C; Berglund UW; Stenmark P; Helleday T
    Cancer Res; 2016 Apr; 76(8):2366-75. PubMed ID: 26862114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico prediction of new inhibitors for the nucleotide pool sanitizing enzyme, MTH1, using drug repurposing.
    Sohraby F; Bagheri M; Javaheri Moghadam M; Aryapour H
    J Biomol Struct Dyn; 2018 Aug; 36(10):2628-2636. PubMed ID: 28818011
    [No Abstract]   [Full Text] [Related]  

  • 26. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
    Shi XL; Li Y; Zhao LM; Su LW; Ding G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer therapy. Targeting the poison within.
    Smits VA; Gillespie DA
    Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
    Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
    Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
    J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
    Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
    Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
    Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
    Aristizabal Prada ET; Orth M; Nölting S; Spöttl G; Maurer J; Auernhammer C
    PLoS One; 2017; 12(5):e0178375. PubMed ID: 28542590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of residue in the position of 116 on the inhibitory potency of TH588 for MTH1.
    Niu RJ; Zheng QC; Zhang HX
    J Mol Graph Model; 2018 Oct; 85():75-83. PubMed ID: 30103119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
    Stebbins JL; Zhang Z; Chen J; Wu B; Emdadi A; Williams ME; Cashman J; Pellecchia M
    J Med Chem; 2007 Dec; 50(26):6607-17. PubMed ID: 18038971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.
    Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock I; Sahasrabudhe P; Bonin P; Hay DA; Brennan PE; Pletcher M; Jones LH; Chekler ELP
    J Med Chem; 2017 Jul; 60(13):5349-5363. PubMed ID: 28375629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological characterisation and application of human MTH1 and monoclonal antibody preparation.
    Chen C; Li X; Gu M; Di R; Kang N; Wang L; Lai Y; Liu Y; Ji X
    Oncol Rep; 2019 Mar; 41(3):1851-1862. PubMed ID: 30569141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.
    Zhou H; Jian Y; Leng Y; Liu N; Tian Y; Wang G; Gao W; Yang G; Chen W
    Int J Hematol; 2017 Mar; 105(3):318-325. PubMed ID: 27848179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.
    Gibbs AC; Abad MC; Zhang X; Tounge BA; Lewandowski FA; Struble GT; Sun W; Sui Z; Kuo LC
    J Med Chem; 2010 Nov; 53(22):7979-91. PubMed ID: 21033679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species.
    Qing X; Shao Z; Lv X; Pu F; Gao F; Liu L; Shi D
    Anticancer Drugs; 2018 Apr; 29(4):341-352. PubMed ID: 29420337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.